apo - clopidogrel/aspirin 75/100, clopidogrel (as hydrogen sulfate)/aspirin 75mg/100mg tablet blister pack
apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -
apo-dipyridamole/aspirin 200/25 dipyridamole/aspirin 200 mg/25 mg modified release capsules bottle
apotex pty ltd - aspirin,dipyridamole -
clopidogrel/aspirin-zp 75/100 clopidogrel (as hydrogen sulfate) and aspirin 75 mg/100 mg uncoated tablet blister pack
medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: crospovidone; glycerol dibehenate; lactose; hydrogenated castor oil; microcrystalline cellulose; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
clopidogrel/aspirin-medis 75/100 clopidogrel (as hydrogen sulfate) and aspirin 75 mg/100 mg uncoated tablet blister pack
medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; microcrystalline cellulose; crospovidone; hydrogenated castor oil; glycerol dibehenate; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
piax plus aspirin 75/100 clopidogrel (as hydrogen sulfate) and aspirin 75 mg/100 mg uncoated tablet blister pack
medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; crospovidone; glycerol dibehenate; hydrogenated castor oil; microcrystalline cellulose; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
aspirin 300mg effervescent tablets
bayer limited - aspirin - effervescent tablet - 300 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid
diasp sr dipyridamole/aspirin 200 mg/25 mg modified release capsules bottle
arrow pharma pty ltd - aspirin,dipyridamole -
millispirin acetyl salicylic acid soluble tablets 300 mg (aspirin)
unimed sdn bhd - aspirin -
bayer aspirin
bayer new zealand limited - aspirin 300mg - tablet - 300 mg - active: aspirin 300mg
dispersible aspirin
multichem nz limited - aspirin 300mg; - dispersible tablet - 300 mg - active: aspirin 300mg excipient: colloidal silicon dioxide hyprolose lactose monohydrate maize starch stearic acid